Trial Profile
Efficacy and tolerability of combination therapy with aprepitant, palonosetron, and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy for gynecological cancer (Phase II Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 28 Jun 2012 New trial record